Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update Received U.S. Food and Drug Administration (FDA) approval for IBTROZI (taletrectinib), a next-generation oral treatment for advanced

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Received U.S. Food and Drug Administration (FDA) approval for IBTROZI

(taletrectinib), a next-generation oral treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) on June 11, 2025

Successfully started 70 patients on IBTROZI as of July 31, 2025, approximately seven weeks after U.S. FDA approval

National Comprehensive Cancer Network added taletrectinib (IBTROZI) as a Preferred

Option to Clinical Practice Guidelines in Oncology for advanced ROS1+ NSCLC on June 20, 2025

Strong balance sheet with cash,

cash equivalents, and marketable securities of $607.7 million as of June 30, 2025

Company to host a conference call today

New York, August 7, 2025 Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of

the toughest challenges in cancer treatment, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.

With FDA approval of IBTROZI, we re proud of our swift evolution into a commercial-stage company executing

across functions to deliver a differentiated therapy to 70 patients in just seven weeks, said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. Since our launch, we have had the opportunity to make a

difference for patients at all different stages of their journey with advanced ROS1-positive NSCLC, including those who are TKI-na ve, those who have progressed on another TKI or early-line treatment, and

those who have switched from prior therapy due to tolerability issues or desire for a brain-penetrant, next generation ROS1 TKI. We were also very pleased by the incredibly rapid designation of taletrectinib (IBTROZI) as a preferred option in the

NCCN guidelines for advanced ROS1-positive NSCLC across lines of therapy. This recommendation is driven by IBTROZI s efficacy, safety, and once-daily dosing that further underscore its potential to redefine the standard of care.

Dr. Hung continued, Meanwhile, we re advancing our broader pipeline with urgency, moving safusidenib toward one or more pivotal trials in

IDH1-mutant glioma and advancing NUV-1511 through an early study in advanced solid tumors. We look forward to sharing our progress from these programs later this year.

Second Quarter 2025 and Recent Corporate Highlights:

IBTROZI (taletrectinib), ROS1 inhibitor: Advanced ROS1+ NSCLC

Safusidenib, mIDH1 inhibitor: Diffuse IDH1-mutant glioma

NUV-1511, drug-drug conjugate

(DDC): Advanced solid tumors

As of June 30, 2025, Nuvation Bio had cash, cash equivalents, and marketable securities of $607.7 million.

Product Revenue, Net

On June 11, 2025, we

announced that the FDA approved IBTROZI (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer ( NSCLC ). To date, our only source of

product revenue has been from the U.S. sales of IBTROZI. We began shipping IBTROZI to our U.S. customers in June 2025. Product revenue, net from U.S. sales of IBTROZI was approximately $1.2 million for the three months ended June 30,

2025. This product revenue was generated from channel stocking and new patient starts for only 13 business days from FDA approval to the end of June. Some of these new patient starts were enrolled in our Free Trial Program, which typically runs for

only one month, to allow patients to receive needed treatment immediately without waiting for reimbursement approval. We expect patients on this program to generate full commercial revenue in their second month on IBTROZI, and therefore in the third

quarter of 2025. To provide a better view on launch dynamics, the Company has disclosed that as of July 31, 2025, 70 patients have started IBTROZI.

Collaboration and License Agreements Revenue

For the three months ended June 30, 2025, collaboration and license agreements revenue was $3.6 million, compared to $1.4 million for the three

months ended June 30, 2024. The increase was primarily due to a $0.9 million increase in products supply, a $0.2 million increase in royalty revenue and a $1.1 million increase in research and development service revenue under

the collaboration agreement with Innovent. The Company anticipates taletrectinib will be listed on China s National Reimbursement Drug List in 2026.

For the three months ended

June 30, 2025, research and development expenses were $27.4 million, compared to $29.3 million for the three months ended June 30, 2024. The decrease was due to a $4.3 million decrease in third-party costs as the prior

period included costs for the preparation of a New Drug Application (NDA) for taletrectinib for submission to the U.S. FDA and a $1.8 million decrease due to a shift of manufacturing activities toward commercial drug production, offset by a

$3.2 million increase in salaries and other benefits driven by the increase in headcount and a $1.0 million increase in stock compensation primarily related to a one-time charge for the vesting of

performance-based awards upon receiving U.S. FDA approval of taletrectinib.

For the three months ended June 30, 2025, selling, general, and

administrative expenses were $38.5 million, compared to $16.2 million for the three months ended June 30, 2024. The increase was due to a $10.9 million increase in sales and marketing expenses, a $10.3 million increase in

personnel-related costs as a result of the increase in headcount, a $1.5 million increase in stock compensation primarily related to a one-time charge for the vesting of performance-based awards upon

receiving U.S. FDA approval of taletrectinib, a $0.9 million increase in other expenses as a result of systems built to prepare for the commercial launch of taletrectinib, and a $0.4 million increase in occupancy expenses offset by a

$0.6 million decrease in professional fees, a $0.5 million decrease in legal fees, and a $0.6 million decrease in foreign currency impact.

For the three months ended June 30, 2025, Nuvation Bio reported a net loss of $59.0 million, or $(0.17) per share. The net loss for the comparable

period in 2024 was $462.5 million, or $(1.89) per share, which was driven by the acquisition of AnHeart Therapeutics.

Conference Call and Webcast

Nuvation Bio will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business

updates for the second quarter of 2025.

Investors and the general public are invited to listen to the live webcast and may register on the Investor

Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code

926066. An archived recording will be available on Nuvation Bio s website for 90 days following the event.

Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common

form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common

site of disease progression, with about 50% of previously treated patients developing CNS metastases. Despite recent progress for patients with ROS1+ NSCLC, there remains a need for more effective and tolerable treatment options.

IBTROZI is an oral, potent, central

nervous system-active, selective, next-generation ROS1 inhibitor therapy approved for the treatment of adult patients with advanced ROS1-positive non-small cell lung cancer. Learn more at IBTROZI.com.

About the TRUST Clinical Program

program evaluating IBTROZI for the treatment of adult patients with advanced ROS1+ NSCLC included two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China,

which enrolled 173 patients, and TRUST-II (NCT04919811), a global study, which enrolled 164 patients. The primary endpoint of these registrational studies is confirmed objective response rate (cORR) as

assessed by an independent review committee (IRC). Secondary endpoints include intracranial cORR, duration of response, progression-free survival, and safety.

IBTROZI is indicated for the treatment of

adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC).

INFORMATION FOR IBTROZITM (taletrectinib)

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased

AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).

Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was

caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.

Concurrent elevations in AST or ALT 3 times the

ULN and total bilirubin 2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.

Interstitial Lung Disease

(ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time

to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).

ILD/pneumonitis led to dose interruption in 1.1% of patients, dose

reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.

QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the

risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.

In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec

occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade 3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction

each occurred in 2.8% of patients.

Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors,

and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.

Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade 3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.

Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred

in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).

Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.

Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures.

3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption

occurred in 0.3% of patients.

Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can

cause fetal harm when administered to a pregnant woman.

Among patients who received IBTROZI, the most frequently reported adverse reactions ( 20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness

(22%), rash (22%), constipation (21%), and fatigue (20%). The most frequently reported Grade 3/4 laboratory abnormalities ( 5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase

OTHER CONSIDERATIONS

Please see accompanying full Prescribing Information.

Nuvation Bio is a global oncology

company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients lives. Our diverse pipeline includes taletrectinib (IBTROZI ), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted

cancer treatment; and NUV-868, a BD2-selective BET inhibitor.